These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 23161460)
1. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. Ghezzi A; Rocca MA; Baroncini D; Annovazzi P; Zaffaroni M; Minonzio G; Comi G; Filippi M J Neurol; 2013 Jan; 260(1):327-9. PubMed ID: 23161460 [No Abstract] [Full Text] [Related]
2. FTY720 and central memory: out of sight, out of mind. Slavin AJ; Zamvil SS Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831 [No Abstract] [Full Text] [Related]
3. Trial watch: Phase III promise for oral multiple sclerosis therapy. Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099 [No Abstract] [Full Text] [Related]
4. Reduction of the washout time between natalizumab and fingolimod. de Seze J; Ongagna JC; Collongues N; Zaenker C; Courtois S; Fleury M; Benoilid A; Chanson JB; Blanc F; Mult Scler; 2013 Aug; 19(9):1248. PubMed ID: 23722322 [No Abstract] [Full Text] [Related]
5. Oral fingolimod (gilenya) for multiple sclerosis. Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782 [No Abstract] [Full Text] [Related]
6. [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system]. Aktas O; Ingwersen J; Kieseier B; Küry P; Hohlfeld R; Hartung HP Nervenarzt; 2011 Feb; 82(2):215-25. PubMed ID: 20842337 [TBL] [Abstract][Full Text] [Related]
7. The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis. Fragoso YD; Arruda CC; Arruda WO; Brooks JB; Damasceno A; Damasceno CA; Finkelsztejn A; Finkelsztejn J; Gama PD; Giacomo MC; Gomes S; Goncalves MV; Matta AP; de Morais MM; Oliveira EM; Ribeiro Y; Sato HK; Tauil CB Arq Neuropsiquiatr; 2014 Sep; 72(9):712-4. PubMed ID: 25252236 [TBL] [Abstract][Full Text] [Related]
8. Delayed fingolimod-associated asystole. Espinosa PS; Berger JR Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609 [TBL] [Abstract][Full Text] [Related]
9. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis. Pfender N; Jelcic I; Linnebank M; Schwarz U; Martin R Neurology; 2015 Jun; 84(23):2377-8. PubMed ID: 25957334 [No Abstract] [Full Text] [Related]
10. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276 [TBL] [Abstract][Full Text] [Related]
12. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T; JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031 [TBL] [Abstract][Full Text] [Related]
13. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)]. Popova NF Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166 [No Abstract] [Full Text] [Related]
14. [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations]. Winkelmann A; Löbermann M; Reisinger EC; Zettl UK Nervenarzt; 2012 Feb; 83(2):236-42. PubMed ID: 21845450 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis]. Chiba K; Yoshii N Nihon Yakurigaku Zasshi; 2012 Jun; 139(6):265-74. PubMed ID: 22728990 [No Abstract] [Full Text] [Related]
16. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P; N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952 [TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs. Sormani MP; Bonzano L; Roccatagliata L; De Stefano N Mult Scler; 2011 May; 17(5):630-3. PubMed ID: 21177320 [TBL] [Abstract][Full Text] [Related]
18. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. Laroni A; Brogi D; Morra VB; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL; BMC Neurol; 2014 Apr; 14():65. PubMed ID: 24690227 [TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Chun J; Hartung HP Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941 [TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis: closing in on an oral treatment. Martin R Nature; 2010 Mar; 464(7287):360-2. PubMed ID: 20237554 [No Abstract] [Full Text] [Related] [Next] [New Search]